Nippon Dental University, Chiyoda-ku, Tokyo 102, Japan rTokyo Research Laboratory, KyowaHakko Kogyo Co., Ltd., Tokyo 194, Japan TtThe Kitasato Institute, and School of Pharmaceutical Sciences, Kitasato University, Tokyo 108, Japan (Received for publication March 4, 1989) Amino acyl derivatives of hitachimycin have been synthesized and evaluated their activities including antibacterial, cytocidal against HeLacells and in vivo antitumor against sarcoma 1 80. 1 5 -0 -{tert -Butoxycarbonyl(BOC)-glycyl)hitachimycin (2), 1 5-O-(BOC-/3-alanyl)hitachimycin (4), 15-0-(BOC-(0-te^Bu)-glutamyl)hitachimycin (6) and 15-O-L-alanylhitachimycin (ll) showed comparable in vivo antitumor activity with hitachimycin and the solubility of these compoundswas improved.
Hitachimycin (l)1} »m is a niacrocyclic lactam antibiotic, which shows antitumor3), antibacterial and antiprotozoal activities.
Hitachimycin (1) acts against a cell wall and is incorporated into the membrane phospholipid bilayer, and increases the permeability of the plasma membrane, ultimately leading to lysis and death of the cells4). Furthermore, 1 shows higher antitumor effect in the combination with bleomycin5). However, as hitachimycin is hardly soluble in water and the other organic solvents, it is difficult to administer in in vivo examination. In the previous paper6»7), we have reported the synthesis and antitumor activities of 1 1,15-0-acyl and 1 1,15-carbonate derivatives of hitachimycin, and some of them showed superior antitumor effects in in vivo assay and higher solubility in organic solvents. From the facts, we have been interested about a substituted acyl derivatives bearing the hydrophilic functional group, which is expected to contribute to the solubility of the derivatives. In this paper, we describe the synthesis of amino acyl derivatives of hitachimycin and their in vivo antitumor activities against sarcoma 1 80.
Synthesis
The substitution of amino acyl group to hitachimycin (1) was carried out through the following step shown in Scheme 1. Treatment of 1 in pyridine with dicyclohexylcarbodiimide (DCC) and tert-Scheme 1.
spectively. In the reaction, a small amount of ll,15-di-BOC-amino acylate was found in the reaction mixture as the minor product, but they disappeared during working up procedure. It was thought that the steric hindrance by the 10-OCH3group to the C-ll position prevented the condensation of bulky BOC-aminoacid to the C-ll hydroxyl group, and as a result, a small amount of unstable llenol ester product was hydrolyzed by the treatment with water. In the 13C NMRspectra of these 15-BOC-amino acylates (2~9), the signals assignable to BOCgroup and each acyl group, a downfield shift of the C-15 carbon, and an upfleld shift (/3-shift) of the C-l6 carbon compared with that of 1 were observed, which indicated the hydroxyl group at the C-15 position is substituted. Trifluoroacetic acid9) was found to be the most effective acid to remove the BOCgroup without hydrolysis of ester bond at C-15 position on hitachimycin. The 15-BOC-amino acylates (2~9) was treated with trifluoroacetic acid at room temperature for 10 minutes to give 15-amino acylates (10~17), respectively. The 13C NMRspectrum of each compound (10~17) showed signals assignable to an amino acyl group and its ester carbonyl carbon (d 167.9~175.6). Furthermore the disappearance of the signal corresponded to BOCgroup was shown in each spectrum. Chemical shift values for 13C NMRspectra of all synthesized amino acylates are listed in Table 1 .
Cytocidal and Antibacterial Activities and Retention Time (RT) of Reversed Phase HPLCand Solubility in Water Cytocidal activities against HeLa cells measured by 50% inhibitory concentration (IC50) values, MIC Og/ml) against various bacteria, hemolytic activity, RT of reversed phase HPLC and solubility in water of hitachimycin derivatives are given in Table 2. RT was obtained as an indication of hydrophilicity of the derivative. Amino acyl derivatives (10~17) exhibited rather short RT, indicating the improvement of hydrophilicity of these derivatives. Actually, solubility in water is increased by 5-to 6-fold in the cases of smaller BOC-amino acyl derivatives (2~4), and 20-to 60-fold in the cases of free amino acyl derivatives (10~17).
BOC-Amino acyl derivatives bearing smaller groups showed similar antibacterial activities to Antitumor Activity Antitumor activities (increase in life span : ILS) at optimal doses of hitachimycin derivatives against sarcoma 180 are given in Table 3 . Several BOC-aminoacyl derivatives, such as 15 (6) showed an increased ILS as compared with that of hitachimycin. It is noteworthy that 15- No. Acylgroup £££ -^^ §a bs ml m § (minuteS) (mg/ml) O-L-alanylhitachimycin (ll), 1 5-0-/3-alanylhitachimycin (12) and 1 5-0-s-aminocaproylhitachimycin (17) which have a free amine group and a higher solubilities than hitachimycin showed comparable antitumor activity with hitachimycin. This seems to suggest the possibility of the water soluble derivation of hitachimycin having rational antitumor activity.
Exp eri mental NMRspectra were measured with Jeol FX-90Q and Varian PX-400 spectrometers in CDC13or DMSO solution. Mass spectra were obtained with Jeol D-100 and DX-300 spectrometers at 70 eV. Optical rotations were measured with a Jasco DIP-181 polarimeter. TLCwas performed on pre-coated plates, Merck Kieselgel 60 F254 with CHC13-MeOH(50 : 1). Silica gel column chromatography was performed with Merck Kieselgel 60.
RT in HPLC
HPLCwas performed on a reversed phase silica gel column (Shiseido Co., Ltd., Capcell pack C18 (SG), 4x250mm) with CH3CN-0.2m NaH2PO4(1 :1) as a solvent system8>10). RT was recorded at 1 ml/minute of flow rate with a UVmonitor (300 nm).
Solubility of Hitachimycin Derivatives to Water Each derivatives (5.0 mg) was taken in the test tube and added to the distilled water (1.0 ml, pH 7.0). The mixture was stirred for 10 minutes and the unsoluble material was removed with centrifugation (3,000 rpm x2 minutes). Each clear solution (10 /d) was charged on HPLCand analyzed with the same method described above. Concentration of each compoundwas calculated from the peak area compared with the standard curve of each compound.
MICs
MICvalues against various bacteria were determined by the agar dilution method using heart infusion agar (pH 7.0).
Cytocidal Activities HeLaS3 cells were maintained in monolayers in Eagle's minimumessential mediumsupplemented with 10% bovine serum and kanamycin (100 /^g/ml) at 37°C. To determine the cytocidal activities of hitachimycin derivatives, HeLa S3 cells (5 x l04) in 1.5 ml of medium were placed in a tissue culture plate (Falcon, 24-well) and incubated for 24 hours at 37°C in a 5% CO2-95% air atmosphere. Each culture well was treated with 0.5 ml of fresh mediumcontaining a different concentration of hitachimycin, and reincubated for 72 hours. The cells were trypsinized to form a single cell suspension, and were counted in a hemocytometer.
Antitumor Activity Sarcoma 180 cells (1 x 106 cells/mouse) were inoculated ip into ICR mice on day-O. Mice received various doses (<250 mg/kg) of hitachimycin derivatives for 5 successive days from day-1. Antitumor activity was evaluated by the increased ILS : (T/C-1) x 100% at the optimal dose for each derivatives, where "T" is the median survival days (MSD)of the treated group and "C" is the MSDof the control group.
1 5-O-(BOC-Glycyl)hitachimycin (2) To a solution of 1 (300mg) and BOC-glycine (150 mg) in pyridine (3.0 ml), DCC (300 mg) was added and stirred for 4 hours at room temperature. After an addition of a drop of H2Oto the reaction mixture, a colorless precipitate was filtered off. The filtrate was diluted with CHC13(50 ml) and washed with H2O. The CHC13layer was dried over anhydrous sodium sulfate and evaporated under reduced pressure, to give a brown solid, which was chromatographed on a silica gel column with CHC13-MeOH(50:1) to afford a colorless powder of 2, 235mg (58. 1 5-O-(BOC-L-Alanyl)hitachimycin (3) To a solution of 1 (300 mg) and BOC-L-alanine (150 mg) in pyridine (3.0 ml), DCC (300 mg) was added and stirred for 12 hours at room temperature. After an addition of a drop of H2Oto the reaction mixture, a colorless precipitate was filtered off. The filtrate was diluted with CHC13(50 ml) and washed with H2O. The CHC13layer was treated in a similar manner to the preparation of 2, to Anal Calcd for C43H58N2O10: C 67.68, H 7.67, N 3.67.
Found: C 67.42, H 7.59, N 3.61.
1 5-O-(BOC-L-Aminobutyryl)hitachimycin (7) Compound 7 was prepared from 1 (400 mg) and BOC-L-aminobutyric acid (150 mg) with DCC (300 mg) as described in the preparation of 3, to give a colorless powder of 7, 273 mg (49.2%): MP 151~154°C (dec); M2D3 +79°(c 0.5, CHC13); UV7Si2H nm (e) 302 (32,100) Anal Calcd for C31H38N2O6 : C 69.63, H 7.17, N 5.24. Found: C 69.50, H 7.ll, N 5.20. 1 5-O-L-Alanylhitachimycin (ll) To a solution of 3 (150mg) in CHC13 (2.0ml), TFA (0.05 ml) was added and set for 10 minutes at roomtemperature. The reaction mixture was treated in a similar manner to the preparation of 
